HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Called Out For “Hypocrisy” Of Conflicting Dove, Axe Ad Campaigns

This article was originally published in The Rose Sheet

Executive Summary

Unilever has come under fire for the seemingly contrary messages of Dove and Axe, two of its biggest brands and most buzzed-about advertising campaigns

You may also be interested in...



Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

The Evolution Of Unilever's AXE: From Babe Magnet To Personal Guru

AXE is taking a "bold new direction" with its marketing, encouraging men to celebrate their uniqueness and look to AXE for its product innovations and grooming advice, rather than the brand's irresistible aphrodisiac powers promoted in the past. The Unilever unit is targeting new "Find Your Magic" messaging to consumers in the US and abroad with cross-channel advertising, including a video created by 72andSunny Amsterdam.

In Brief

Synoia Technologies seeks “fastest” status for its anti-aging aesthetic device, P&G recalls select Crest & Scope oral-rinse products and Avon finishes refinancing. More news in brief.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel